How do you choose between neoadjuvant and adjuvant chemo-immunotherapy for patients with resectable stage II-IIIA NSCLC?  

In light of CheckMate 816 and IMpower010 and FDA approval for neoadjuvant chemo-nivolumab and adjuvant chemo-atezolizumab, how do you decide which systemic therapy/order to offer? Does the shorter duration of immunotherapy with nivoluamb play a role in your decision making? 

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice